Peplin completes Neosil buy
Monday, 20 October, 2008
Peplin has completed its US$6.7 million purchase of private dermatology company Neosil.
The Brisbane biotech issued shares iin common stock in exchange for all equity interests in Neosil, which is developing a topical hair growth product and a broad-spectrum topical anti-microbial agent for acne.
Peplin shareholders have also approved a private placement of stock to raise US$24 million to help fund its Phase III trial of PEP005, a topical gel for sun spots.
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
